Financial Performance - The Group achieved a turnover of RMB14,151,000 for the Period, representing a decrease of 46.04% from RMB26,226,000 compared to the corresponding period of 2021[25]. - The Group achieved profit before taxation of RMB8,465,000 for the Period, representing a decrease of 44.68% from RMB15,303,000 compared to the corresponding period of 2021[25]. - Basic and diluted earnings per share are RMB0.73 cents for the Period, representing a decrease of 45.11% from RMB1.33 cents compared to the corresponding period of 2021[26]. - The Group's unaudited net profit for the Period is approximately RMB7,289,000, down from RMB13,184,000 in 2021[16]. - For the three months ended 31 March 2022, the company reported a net profit of approximately RMB 7,289,000, a decrease of 44.8% compared to RMB 13,184,000 for the same period in 2021[32]. - Gross profit for the period was RMB 10,598,000, representing a decline of 46.2% from RMB 19,670,000 in the prior year[38]. - Profit from operations was RMB 8,449,000, down 44.5% from RMB 15,317,000 in the previous year[38]. - The Group recorded a turnover of RMB 14,151,000 for the three months ended 31 March 2022, representing a decrease of 46.04% from RMB 26,226,000 in the corresponding period of last year[118]. - Net profit for the period was approximately RMB 7,289,000, down 44.68% from RMB 13,183,000 in the same period of 2021[120]. Taxation and Dividends - No provision for Hong Kong Profits Tax has been made as the Group had no estimated assessable profits for the Period (2021: Nil)[19]. - The applicable income tax rate for PRC Enterprise Income Tax ranges from 9% to 25% as at 31 March 2022[20]. - The Board does not recommend the payment of any dividend for the three months ended 31 March 2022 (for the three months ended 31 March 2021: Nil)[22]. - The applicable income tax rate for the company and its subsidiaries ranges from 9% to 25% as of 31 March 2022, with some subsidiaries benefiting from a preferential tax rate of 9%[35]. - The company had no estimated assessable profits for Hong Kong Profits Tax for the period, similar to the previous year[34]. - The Group did not recommend any dividend payment for the three months ended 31 March 2022, consistent with the previous year[142]. Administrative Expenses - Administrative expenses for the quarter were RMB 2,197,000, a reduction of 50.3% compared to RMB 4,418,000 in the same period last year[38]. - Total consolidated administrative expenses and staff costs for the period were approximately RMB 2,197,000, compared to approximately RMB 4,418,000 in the previous year[119]. - Administrative expenses decreased by 50.27% compared to the corresponding period of 2021, amounting to RMB4,418,000[70]. Share Information - The weighted average number of ordinary shares for the Company for the Quarter is 995,351,660 shares[16]. - Basic earnings per share for the quarter were 0.73 cents, down from 1.33 cents in the same quarter of 2021[38]. - Basic earnings per share for the quarter was calculated based on a weighted average of 995,351,660 ordinary shares, with no adjustments made for dilution effects[71]. - Basic earnings per share for the quarter was calculated by dividing the net profit of approximately RMB 7,289,000 by the weighted average number of 995,351,660 ordinary shares[109]. Corporate Governance - The Company has complied with the Corporate Governance Code, except for the lack of a separate CEO, as the position has not yet been filled[191]. - The company emphasizes the quality, transparency, and accountability of its Board, although the roles of Chairman and CEO have not been separated due to the absence of a CEO appointment[192]. - The Audit Committee, consisting of three independent non-executive Directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[194]. Business Strategy and Operations - The Group has launched a value-added business model focusing on treatment products across the entire value chain, with sub-brands including Xienwanquan and Baimin Wanquan[121]. - The Group's "RWS Wanquan center" aims to re-screen existing drugs through real clinical research to find optimal treatments[99]. - The Group has established a biological sample testing laboratory to support clinical research, particularly for antiviral drugs[99]. - The Group is investing in enhancing its market promotion ability and expanding its market network in response to changes in the business model of Chinese pharmaceutical enterprises[121]. Shareholder Information - Winsland Agents Limited beneficially owns 349,368,873 shares, representing approximately 35.10% of the total issued shares of the Company[186]. - Bright Excel Assets Limited holds 91,915,181 shares, accounting for about 9.23% of the total issued shares[186]. - Venturepharm Holdings Inc. beneficially owns 149,432,583 shares, which is approximately 15.01% of the total issued shares[186]. - As of March 31, 2022, no other individuals were recorded as having interests or short positions in the shares of the Company[188]. - The Company has not been notified of any interests or short positions of the Directors and chief executive in the shares as of March 31, 2022[180]. Compliance and Reporting - These condensed consolidated financial statements were approved by the Board on 6 May 2022[24]. - The consolidated financial statements were approved by the board on 6 May 2022[87]. - The company has adopted a code of conduct for securities transactions by Directors, complying with the standards set out in Rules 5.48 to 5.67 of the GEM Listing Rules[193]. - The company has not yet applied the new Hong Kong Financial Reporting Standards that have been issued but not yet effective[55].
中国医疗集团(08225) - 2022 Q1 - 季度财报